Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Multiple Myeloma - Overview - Disease Synopsis

Drugs & Clinical Candidates


17 drugs have received FDA approval for Multiple Myeloma . Bortezomib, Carfilzomib, Carmustine, Cyclophosphamide, Daratumumab, Denosumab, Doxorubicin Hydrochloride, Elotuzumab, Ixazomib citrate, Lenalidomide, Melphalan Hydrochloride, Pamidronate Disodium, Panobinostat, Plerixafor Octahydrochloride, Pomalidomide, Thalidomide and Zoledronic Acid
360 drugs have a clinical trial registered for Multiple Myeloma.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 2055 clinical trials for Multiple Myeloma,
1544 of which have one or more drug interventions,
511 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 118 Cell Line Models for Multiple Myeloma.

Source: COSMIC
(see details)

Chemistry


There are 6635 Compounds which have been tested in Multiple Myeloma , 4584 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Multiple Myeloma:
Multiple Myeloma
Smoldering Multiple Myeloma

The following terms have been mapped from cancer.gov to Multiple Myeloma:
Broken bones and other bone problems caused by multiple myeloma or by solid tumors that have metastasized (spread) to bone. This use is approved for the Xgeva brand of denosumab
Multiple myeloma
Multiple myeloma and cancers that have spread to the bone
Multiple myeloma in patients who have already received at least one other type of treatment
Multiple myeloma in patients who have already received one to three other types of treatment
Multiple myeloma in patients who have just been diagnosed with the disease
Multiple myeloma that has gotten worse during or after treatment with at least two other drugs, including lenalidomide and bortezomib
Multiple myeloma that has metastasized to bone
Multiple myeloma. It is given with dexamethasone. It is also used alone as maintenance therapy in patients who received an autologous stem cell transplant
Multiple myeloma. It is used in patients who have already received at least two other standard treatments, including bortezomib and an immunomodulating agent
Multiple myeloma. It is used with bortezomib in patients who have already been treated with other chemotherapy
Multiple myeloma. It is used with dexamethasone and either bortezomib or lenalidomide in patients who have already received at least one other type of treatment
Multiple myeloma. It is used with prednisone
Multiple myeloma.It is used for palliative treatment in patients who cannot take melphalan by mouth. This use is approved for the Alkeran and Evomela brands
Multiple myeloma.It is used with lenalidomide and dexamethasone in patients whose disease has recurred (come back) and who have already received one to three other types of treatment